Evidence map›Paper›PMID 41873153›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Discovery of ferulic acid carbamate derivatives as dual-targeting agents of BuChE and Nrf2 for Alzheimer's disease.

Kejing Lao, Yingze Li, Yueyan Xiao, Ya Sun, Yuxuan Dai, Huijin Li, Yang Yang, Yun Zhang, Jing Wang, Weize Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kejing LaoShaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Yingze LiShaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Yueyan XiaoShaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Ya SunShaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Yuxuan DaiShaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Huijin LiShaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Yang YangCollege of Pharmacy, Xi'an Medical University, Xi'an, China.
Yun ZhangCollege of Pharmacy, Xi'an Medical University, Xi'an, China.
Jing WangCollege of Pharmacy, Xi'an Medical University, Xi'an, China.
Weize LiCollege of Pharmacy, Xi'an Medical University, Xi'an, China.
Xingchun GouShaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.
Li GuanCollege of Pharmacy, Xi'an Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the multifactorial aetiology of Alzheimer's disease, multi-target strategies have emerged as a promising therapeutic approach. In this study, we designed and synthesised a series of ferulic acid carbamate derivatives to selectively inhibit BuChE and stimulate Nrf2 pathway. The biological evaluation revealed that compound

Indexed as

Alzheimer DiseaseButyrylcholinesteraseCarbamatesCholinesterase InhibitorsCoumaric AcidsDrug DiscoveryNF-E2-Related Factor 2Amyloid beta-PeptidesAnimalsCaenorhabditis elegansDose-Response Relationship, DrugHumansMiceMolecular StructureOxidative StressStructure-Activity RelationshipAmyloid beta-PeptidesButyrylcholinesteraseCarbamatesCholinesterase InhibitorsCoumaric Acidsferulic acidNF-E2-Related Factor 2Alzheimer’s diseaseBuChE inhibitorferulic acidNrf2 pathway

Identifiers

PMID41873153
PMCPMC13015032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.